Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has announced the development and upcoming launch of the new version of its proprietary V-OVS® syringe closure system.
The new closure, V-OVS® next, will further advance a proprietary system with many years of proven market success supporting and differentiating a range of sterile injectables. This latest evolution will integrate several unique technical advances guided by both shifting market needs and feedback from the many customers who have selected V-OVS® for their products.
Similar to the original system, the design of V-OVS® next will be optimized to protect the integrity of the injectable product secured by the closure. For customers with products in glass-barrel syringes, this new closure will be an opportunity to integrate gold-standard Luer Lock features with even easier handling characteristics and an even more intuitive opening mechanism.
“With its proprietary tamper-evident features, we’re confident that V-OVS® next will bring a new level of user-friendliness to Luer Lock applications,” says Tobias Nemeth, Director Primary Packaging Service & Projects at Vetter. “It will further build on the decades of market impact delivered by this industry-leading system, and provide a differentiating choice for customers with an even wider range of injectable products.” In addition to handling enhancements, the overall size will also be reduced to better fit smaller syringe sizes. New updated gripping surfaces will provide optimal control during opening, and a robust new locking mechanism will help keep the closure safely in place even during the most challenging clinical use cases.
While still in development, Vetter has already placed V-OVS® next on a launch pathway for 2027. For now, the focus remains on finalizing the system’s design and further advancing its commercialization. As part of its go-to-market preparations, Vetter recently conducted a successful human factors study with a representative group of frontline clinical users. The study delivered consistent positive feedback and insights that will directly contribute to finalizing the design of the new closure system.
For more information, visit www.vetter-pharma.com
